Parvin Kachoie-Ataie

St. George Hospital Kogarah
Kogarah, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Erratum: Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies.

Erratum: Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies.

Journal: American journal of cancer research

Published: January 29, 2025

Retraction: Minocycline Targets the NF-κB Nexus through Suppression of TGF-β1-TAK1-IκB Signaling in Ovarian Cancer.

Retraction: Minocycline Targets the NF-κB Nexus through Suppression of TGF-β1-TAK1-IκB Signaling in Ovarian Cancer.

Journal: Molecular cancer research : MCR

Published: April 02, 2024

Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies.

Monepantel considerably enhances the therapeutic potentials of PEGylated liposomal doxorubicin and gemcitabine in ovarian cancer: in vitro and in vivo studies.

Journal: American journal of cancer research

Published: August 04, 2018

Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies.

Minocycline attenuates hypoxia-inducible factor-1α expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies.

Journal: American journal of cancer research

Published: November 04, 2014

p70 Ribosomal protein S6 kinase (Rps6kb1): an update.

p70 Ribosomal protein S6 kinase (Rps6kb1): an update.

Journal: Journal of clinical pathology

Published: August 08, 2014

Gene of the month: Interleukin 6 (IL-6).

Gene of the month: Interleukin 6 (IL-6).

Journal: Journal of clinical pathology

Published: July 18, 2014

Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer.

Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer.

Journal: Molecular cancer research : MCR

Published: July 17, 2013

Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.

Journal: PloS one

Published: November 28, 2012

Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways.

Minocycline inhibits malignant ascites of ovarian cancer through targeting multiple signaling pathways.

Journal: Gynecologic oncology

Published: October 31, 2012

Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.

Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.

Journal: Cytokine & growth factor reviews

Published: September 06, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026